Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis | Synapse

October 1, 2021Open Access

Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis

FTFranziska ThalerLMU Klinikum LZLuise ZimmermannHeidelberg University SKStefan KammermeierLMU Klinikum

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This study provides Class IV evidence that rituximab is an effective treatment for some types of AE.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Thaler et al. (Fri,) studied this question.

synapsesocial.com/papers/69d72cb33f906f6a06bef989 https://doi.org/https://doi.org/10.1212/nxi.0000000000001088

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)2013 · 604 citations
2B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis2008 · 2,417 citations
3Stiff person syndrome2001 · 215 citations
4Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome2020 · 60 citations
5Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management2021 · 162 citations